Effect of CGM on Glucose Control in Non-insulin-treated Patients with Type 2 Diabetes Mellitus

Inclusion Criteria:

• (1)Subjects aged ≥18 years at screening (based on the day of signing the informedconsent form) and of any gender

• (2)Patients diagnosed with type 2 diabetes

• (3)Prior to the screening, glycemic control was suboptimal with diet, exercisecontrol, and oral medication or glucagon-like peptide-1RA (GLP-1RA) therapymaintained for more than 3 months, 7.5%≤HbA1c≤10%

• (4)Subjects voluntarily sign an informed consent form

Exclusion Criteria:

• (1)Patients treated with insulin within 3 months prior to screening

• (2)Currently or have used a CGM device within 3 months prior to enrollment

• (3)Serious skin disease at the sensor placement site, allergy to tape or adhesives

• (4)Pregnant females, those with a positive pregnancy test result at screening, orthose who plan to become pregnant during the study

• (5)Those who are participating or will participate in other clinical trials

• (6)Those who, in the opinion of the investigator, should not participate in thisclinical trial, such as: ①those who have a history of eye trauma or other diagnosedeye diseases resulting in visual impairment, etc.; ②those who are unwilling orunable to fully understand or cooperate due to speech disorders; ③those who sufferfrom mental disorders